OSUR vs QGEN
OSUR: OrasuRe is a diagnostic company specializing in rapid point-of-care and self-test solutions for infectious diseases and rare conditions, with recent expansion into sickle cell screening through the BioMedomics acquisition. QGEN: QIAGEN supplies essential molecular diagnostic and sample preparation tools that enable laboratories and clinicians to detect, analyze, and validate genetic material and biomarkers.
Side-by-side fundamentals
| Metric | OSUR | QGEN | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $3.96 | $41.08 | |
| Market cap as of 2026-07-29 | $273M | $8.6B | |
| P/E as of 2026-07-29 | n/a | 21.76 | |
| PEG as of 2026-07-29 | -0.03 | 3.13 | OSUR lower |
| Net margin as of 2026-07-29 | -66.4% | +19.2% | QGEN higher |
| Gross margin as of 2026-07-29 | +42.5% | +62.6% | QGEN higher |
| Operating margin as of 2026-07-29 | -68.6% | +20.7% | QGEN higher |
| ROE as of 2026-07-29 | -21.5% | +11.3% | QGEN higher |
| ROA as of 2026-07-29 | -18.2% | +6.6% | QGEN higher |
| Debt / equity as of 2026-07-29 | 0.00 | 0.49 | OSUR lower |
| Revenue growth (YoY) as of 2026-07-29 | -30.1% | +4.8% | QGEN higher |
| Revenue CAGR (3y) SEC XBRL | -33.3% | n/a | |
| Dividend yield as of 2026-07-29 | n/a | +0.6% | |
| Beta as of 2026-07-29 | 1.04 | 0.63 | |
| 1-year return as of 2026-07-27 close | +17.9% | -20.7% | OSUR higher |
Fundamentals: Finnhub, as of 2026-07-29. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.